Intravenous iron administration strategies and anemia management in hemodialysis patients
Open Access
- 6 September 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (1) , 173-181
Abstract
Background. The effect of maintenance intravenous (IV) iron administration on subsequent achievement of anemia management goals and mortality among patients recently initiating hemodialysis is unclear. Methods. We performed an observational cohort study, in adult incident dialysis patients starting on hemodialysis. We defined IV administration strategies over a 12-week period following a patient's initiation of hemodialysis; all those receiving IV iron at regular intervals were considered maintenance, and all others were considered non-maintenance. We used multivariable models adjusting for demographics, clinical and treatment parameters, iron dose, measures of iron stores and pro-infectious and pro-inflammatory parameters to compare these strategies. The outcomes under study were patients' (i) achievement of hemoglobin (Hb) of 10–12 g/dL, (ii) more than 25% reduction in mean weekly erythropoietin stimulating agent (ESA) dose and (iii) mortality, ascertained over a period of 4 weeks following the iron administration period. Results. Maintenance IV iron was administered to 4511 patients and non-maintenance iron to 8458 patients. Maintenance IV iron administration was not associated with a higher likelihood of achieving an Hb between 10 and 12 g/dL {adjusted odds ratio (OR) 1.01 [95% confidence interval (CI) 0.93–1.09]} compared with non-maintenance, but was associated with a higher odds of achieving a reduced ESA dose of 25% or more [OR 1.33 (95% CI 1.18–1.49)] and lower mortality [hazard ratio (HR) 0.73 (95% CI 0.62–0.86)]. Conclusions. Maintenance IV iron strategies were associated with reduced ESA utilization and improved early survival but not with the achievement of Hb targets.Keywords
Funding Information
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- Agency for Healthcare Research and Quality (HHSA290200500341I)
- Postdoctoral Full Fellowship Abroad (KFB 11.005)
- Nierstichting (K23DK097184)
- Gilbert S. Omenn Anniversary Fellowship of the Institute of Medicine (K23DK083514, K23DK095949)
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 19 references indexed in Scilit:
- Trends in anemia management in US hemodialysis patients 2004–2010BMC Nephrology, 2013
- Intravenous Iron Supplementation Practices and Short-Term Risk of Cardiovascular Events in Hemodialysis PatientsPLOS ONE, 2013
- Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease studyBMC Nephrology, 2012
- An improved comorbidity index for outcome analyses among dialysis patientsKidney International, 2010
- KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin TargetAmerican Journal of Kidney Diseases, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized studyPediatric Nephrology, 2004
- A study of parenteral iron regimens in hemodialysis patientsAmerican Journal of Kidney Diseases, 1999
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998